Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-RESCA-RB14 is a radiopharmaceutical compound designed for positron emission tomography (PET) imaging. It utilizes the fluorine-18 isotope, which is well-suited for PET due to its favorable half-life and imaging properties. The RESCA chelator enables efficient and mild radiolabeling of peptides, proteins, or biologics with fluorine-18 via the Al[18F]F method. This approach allows rapid, one-step synthesis under Good Manufacturing Practices (GMP), making it suitable for clinical applications where high image resolution and centralized production are advantageous. The specific biological target or indication of RB14 is not detailed in available sources; however, compounds labeled with [18F] using RESCA are typically developed as molecular imaging agents to visualize specific targets in oncology or other disease areas[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]F-RESCA-RB14.